CDBI Partners is a private equity investment firm that provides strategic and financial support for Chinese investment fund healthcare and TMT sector.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
CDBI Partners is a private equity investment firm that provides strategic and financial support for Chinese investment fund healthcare and TMT sector.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2022 | Acchrom Tech | Angel Round | 14.5M |
1/2019 | accunome | Series A | - |
7/2019 | Xinzhi Medical | Seed Round | - |
5/2021 | Reliable Med | Series A | - |
2/2016 | Righton | Series A | - |
5/2016 | Shenzhen Kuaiyijian Network Technology | Angel Round | - |
7/2021 | Westlake Therapeutics | Venture Round | 0 |
5/2022 | Full-Life Technologies | Series A | 0 |
12/2019 | Bioheart | Series B | - |
4/2018 | CMAB BioPharm | Series B | 0 |
9/2022 | Neukio Biotherapeutics | Series A | 50M |
3/2022 | Yingsheng Biology | Series C | - |
11/2015 | Sino Vision | Series A | 1.6M |
10/2022 | Xunshi Technology | Series D | 0 |
7/2018 | Shenzhen Kuaiyijian Network Technology | Series B | 15M |
4/2022 | Reliable Med | Series A | 15M |
9/2015 | Med Lighter | Series A | 3.1M |
1/2017 | Microtech Medical | Series B | 12.2M |
12/2017 | 12 Sigma Technologies | Series B | 30.2M |
5/2018 | Jenscare Biotech | Series A | - |
12/2020 | WT Microtech Medical | Series D | 0 |
4/2019 | Creative Biosciences | Series B | 44.7M |
1/2017 | Microread | Series A | 1.5M |
8/2018 | Urotronic | Series B | 20M |
4/2016 | Percutek Therapeutics | Series B | - |
12/2016 | WT Microtech Medical | Series B | - |
7/2017 | Creative Biosciences | Series A | 9M |
11/2020 | Yingsheng Biology | Series B | - |
9/2017 | Smartee Denti-Technology | Series B | 7.6M |
6/2015 | Biomarker Technologies | Series B | 16.2M |
8/2016 | Singlera Genomics | Series A | 20M |
12/2021 | Wancheng Gene | Series A | 15.7M |
5/2021 | Jenscare Biotech | Venture Round | - |
12/2019 | Hui-Gene Therapeutics | Series A | 14.2M |
5/2022 | Hui-Gene Therapeutics | Series C | - |
9/2021 | FORQALY | Series B | - |
10/2018 | celula | Angel Round | 0 |
8/2016 | Sino Vision | Series B | 3M |
1/2021 | SeekGene | Series A | 15.4M |
5/2015 | Sino Vision | Series A | 3.2M |
11/2019 | Bioheart | Series B | 8.5M |
10/2022 | SprintRay | Series D | 0 |
3/2016 | Superbio | Series A | 3.3M |
5/2019 | Pulse Medical | Series A | 1.4M |
5/2022 | Full-Life Technologies | Series A | 0 |
5/2022 | Hui-Gene Therapeutics | Series C | - |
4/2022 | Reliable Med | Series A | 0 |
3/2022 | Yingsheng Biology | Series C | - |
12/2021 | Wancheng Gene | Series A | 0 |
9/2021 | FORQALY | Series B | - |
7/2021 | Westlake Therapeutics | Venture Round | 0 |
5/2021 | Jenscare Biotech | Venture Round | - |
5/2021 | Reliable Med | Series A | - |
1/2021 | SeekGene | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|